---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265810"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:29:51.771829+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition

## Summary
- Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).
- GAAP net income $8.0M ($0.03 EPS) vs $11.6M in Q3 2024; non-GAAP net income $22.4M ($0.07) +45%.
- Completed scPharmaceuticals acquisition Oct 7 with ~$133.2M cash & $250M in delayed draw term loans.
- Afrezza pediatric sBLA accepted (PDUFA May 29, 2026); FUROSCIX sNDA submitted; MNKD-101 & MNKD-201 trials advancing.
- Appointed Dr. Ajay Ahuja as CMO; cash & investments $286.3M at Sep 30.

## SEC filing metadata
- accession: 0001193125-25-265810
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/0001193125-25-265810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265810
- JSON: https://secwatch.observer/filing/0001193125-25-265810.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.